Cancer. 2009 Jul 15;115(14):3217-21.

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.

Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H.

Source

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. gborthak@mdanderson.org

Abstract

BACKGROUND:

Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities.

METHODS:

A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%.

RESULTS:

Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis.

CONCLUSIONS:

Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

PMID:: 19441109; [PubMed - indexed for MEDLINE]

Free full text

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. [Am J Clin Pathol. 2009]
Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.
Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA. Am J Clin Pathol. 2009 May; 131(5):647-55.
Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia. [Leukemia. 1992]
Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia.
Sandoval C, Head DR, Mirro J Jr, Behm FG, Ayers GD, Raimondi SC. Leukemia. 1992 Jun; 6(6):513-9.
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. [Cancer. 2008]
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Cancer. 2008 Dec 1; 113(11):3181-5.
Review Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? [Best Pract Res Clin Haematol. ...]
Review Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA. Best Pract Res Clin Haematol. 2007 Mar; 20(1):29-37.
Review Core binding factor acute myeloid leukemia. [Semin Oncol. 2008]
Review Core binding factor acute myeloid leukemia.
Paschka P. Semin Oncol. 2008 Aug; 35(4):410-7.

See reviews... See all...

Cited by 3 PubMed Central articles

Similarities and differences between therapy-related and elderly acute myeloid leukemia. [Mediterr J Hematol Infect Dis....]
Similarities and differences between therapy-related and elderly acute myeloid leukemia.
D'Alò F, Fianchi L, Fabiani E, Criscuolo M, Greco M, Guidi F, Pagano L, Leone G, Voso MT. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011052. Epub 2011 Nov 28.
Review Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. [Br J Pharmacol. 2011]
Review Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.
Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A. Br J Pharmacol. 2011 Feb; 162(4):792-805.
Temozolomide-induced myelodysplasia. [Adv Hematol. 2010]
Temozolomide-induced myelodysplasia.
Natelson EA, Pyatt D. Adv Hematol. 2010; 2010:760402. Epub 2010 Mar 4.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Survival is poorer in patients with secondary core-binding factor acute myelogen...
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer. 2009 Jul 15 ;115(14):3217-21.

PubMed
The etiology of liver damage imparts cytokines transforming growth factor beta1 ...
The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis.
Hepatology. 2009 Jul ;50(1):230-43.

PubMed
Association between dietary nutrient composition and the incidence of cirrhosis ...
Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population.
Hepatology. 2009 Jul ;50(1):175-84.

PubMed
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identifie...
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
Genes Chromosomes Cancer. 2009 Aug ;48(8):679-93.

PubMed
Hares and tortoises: the high- versus low-throughput proteomic race.
Hares and tortoises: the high- versus low-throughput proteomic race.
Electrophoresis. 2009 Jun ;30 Suppl 1:S150-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.

Source

Abstract

BACKGROUND:

METHODS:

RESULTS:

CONCLUSIONS:

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information